Diagnoptics develops and markets non-invasive diagnostic technologies to assess cardiovascular risk and the risk of diabetes. The extensively validated AGE Reader enables a doctor to non-invasively assess the cardiovascular risk of their patients within 12 seconds. The technology is extensively validated in >250 scientific publications and is currently being marketed internationally. The company brings the AGE Scanner to the wellness markets for the assessment of health and skin ageing.

---

Website: diagnoptics.com